The Independent |
‘Every heart in India is crying today’: India mourns the retirement of Sachin …
The Independent “Every heart in India is crying today. Cricket is over.” On social media, cricket fan and government minister Shashi Tharoor declared that Tendulkar had been the “greatest Indian to wield a bat”. “He has given us all so much,” he added of the man with … Sachin Tendulkar to retire after 200th test, says ‘heart feels it’s time.’NDTV Sachin Tendulkar to retire after 200th, says heart feels it’s time!Indian Express Tendulkar to quit after 200th testReuters India Cricket Country –The Guardian all 353 news articles » |
Cardiac Biomarker ST2 Helps Assess Heart Failure Risk And Identify Heart … – EON: Enhanced Online News (press release)
|
Cardiac Biomarker ST2 Helps Assess Heart Failure Risk And Identify Heart …
EON: Enhanced Online News (press release) SAN DIEGO–(BUSINESS WIRE)–Critical Diagnostics announced today that results of the HF-ACTION study just published in the American Heart Association’s Circulation: Heart Failure demonstrate that levels of the biomarker ST2 are predictive of long-term … |
Indore: Quack's injection turns a girl into psychotic – Daily News & Analysis
Daily News & Analysis |
Indore: Quack’s injection turns a girl into psychotic
Daily News & Analysis … injectible, due to which she is into extrapyramidal symptom (EPS), which is a side affect of anti-psychotic medication.” The girl also developed typhoid, liver malfunction and high levels of blood ammonia during the treatment, the doctors at MY … |
Cardiac Biomarker ST2 Helps Assess Heart Failure Risk And Identify Heart … – 4-traders (press release)
|
Cardiac Biomarker ST2 Helps Assess Heart Failure Risk And Identify Heart …
4-traders (press release) Critical Diagnostics announced today that results of the HF-ACTION study just published in the American Heart Association’s Circulation: Heart Failure demonstrate that levels of the biomarker ST2 are predictive of long-term outcomes for people … |
Rituximab Biosimilar Market Opportunity Analyzed in New Research Report at … – PR Web (press release)
|
Rituximab Biosimilar Market Opportunity Analyzed in New Research Report at …
PR Web (press release) In this report “Therapy Class Overview: Rituximab biosimilar – http://www.reportsnreports.com/reports/269204-therapy-class-overview-rituximab-biosimilar.html ”, we have analyzed the market opportunity of rituximab biosimilar. What one would get if buy … |
Gilead halts leukaemia study on positive results – PMLiVE
|
Gilead halts leukaemia study on positive results
PMLiVE The trial – known as Study 116 – is comparing idelalisib plus Roche/Biogen Idec’s Rituxan (rituximab) to rituximab alone in patients unsuitable for treatment with conventional chemotherapy. At an interim analysis, the combination was found to have a … Gilead Stops Cancer Drug Trial Early On Positive ResultsNASDAQ UPDATE: Gilead to Stop Phase 3 Study 116 of Idelalisib in Chronic Lymphocytic …Benzinga Gilead stops leukaemia drug trial earlyPharmaTimes MarketWatch all 21 news articles » |
Alethia Biotherapeutics obtains US patent for use of anti-Siglec-15 antibodies – Pharmaceutical Business Review
|
Alethia Biotherapeutics obtains US patent for use of anti-Siglec-15 antibodies
Pharmaceutical Business Review The patent entitled ‘Polynucleotides and Polypeptide Sequences involved in the Process of Bone Remodeling’, provides broad protection for antibodies that target Siglec-15 and also having osteoclast differentiation or bone resorption inhibitory activity. |
Glenmark files lawsuit in US court for Hydrocortisone Butyrate cream – Myiris.com
LivemintGlenmark files lawsuit in US court for Hydrocortisone Butyrate creamMyiris.comGlenmark Generics Inc, USA the subsidiary of Glenmark Generics has filed a lawsuit in the court of chancery of the state of Delaware against Astellas Pharma Europe B….
Gilead stops leukaemia drug trial early – PharmaTimes
|
Gilead stops leukaemia drug trial early
PharmaTimes The safety profile of the drug was also found to be “acceptable and consistent with prior experience” when combing it with rituximab in previously treated CLL. Norbert Bischofberger, Gilead’s R&D chief, said the firm is pleased that idelalisib has … |
Heptares' StaR platform offers breakthrough solution to challenge associated … – News-Medical.net
|
Heptares’ StaR platform offers breakthrough solution to challenge associated …
News-Medical.net Heptares’ StaR platform offers a breakthrough solution to the main challenge associated with making antibodies against GPCRs: producing purified, properly folded and functional protein when removed from the cell membrane for use as an antigen. Heptares Delivers First Stabilised GPCR (StaR®) to MorphoSys for Antibody …PR Newswire (press release) |